CorVel Corporation — Form 10-Q Summary
Period discrepancy: The request metadata says 2013 Q1, but the filing is for the quarter ended June 30, 2014 (CorVel’s fiscal 2015 first quarter), compared with the quarter ended June 30, 2013. The company filed the report on August 5, 2014.
Business context and financial performance
CorVel provides medical cost-containment and managed-care services, including patient management and network solutions, primarily to workers’ compensation and auto-claim payors. It reports one operating segment.
| Metric | Quarter ended June 30, 2013 | Quarter ended June 30, 2014 | Change |
|---|---|---|---|
| Revenue | $118.1 million | $124.4 million | +5.3% |
| Gross profit / margin | $26.9 million / 22.8% | $27.7 million / 22.3% | +2.9% / down 0.5 percentage points |
| General and administrative expense | $12.8 million | $14.2 million | +10.6% |
| Income before taxes | $14.1 million | $13.5 million | −4.1% |
| Net income | $8.6 million | $8.3 million | −3.6% |
| Basic / diluted EPS | $0.40 / $0.40 | $0.40 / $0.39 | Diluted EPS down 2.5% |
| Operating cash flow | $16.8 million | $9.7 million | Down $7.1 million |
Patient management accounted for 52.6% of revenue, up from 51.9%; network solutions accounted for 47.4%, down from 48.1%. The filing reports no separate segment profit. The 2014 quarter’s net margin was approximately 6.7%, versus 7.3% a year earlier.
Liquidity, debt and capital allocation
- At June 30, 2014, cash and cash equivalents were $34.1 million; working capital was $52.0 million. Cash was down $0.7 million from March 31, 2014.
- CorVel had no debt outstanding. Its revolving credit facility provides up to $10 million, with $4.5 million of letters of credit issued separately; the facility was due to expire in September 2014.
- Quarterly investing cash outflow was $5.4 million, including $4.6 million for property and equipment and an $0.8 million private-equity investment. Financing cash outflow was $5.0 million, including $5.7 million of share repurchases.
- The company repurchased 123,446 shares during the quarter for $5.7 million, at an average $46.35 per share. After quarter-end through July 23, it repurchased another 35,566 shares for $1.6 million.
- Contractual obligations totaled $60.5 million, including $57.4 million in operating leases. The company also expects to fund the remaining $1.2 million commitment to its private-equity investment within 12 months.
Material changes, outlook and risks
- Revenue growth was primarily driven by patient-management TPA services, which increased 6.6%; network-solutions revenue increased 3.8%. Management attributed about 80% of total revenue growth to new TPA customer services and expected that contribution to continue in the coming year.
- Cost of revenue grew faster than revenue because of a greater mix of lower-margin TPA services; salaries and pharmacy costs were notable contributors. G&A rose 10.6%, mainly due to IT spending for a new data center, programming, salaries and consultants. These factors reduced pretax income despite higher revenue.
- Operating cash flow fell chiefly because of lower bonus accruals and other accrued liabilities. Management said cash and expected internally generated funds should cover obligations, repurchases and planned business investment for at least the next 12 months. No specific earnings or revenue guidance was provided.
- Management identified risks including competition and customer insourcing, fewer workers’ compensation claims, pricing and margin pressure, labor costs and staffing, regulatory changes, litigation, data-security or system interruptions, and the ability to develop and implement software. The filing notes seasonal effects from working days, particularly fewer working days in the third fiscal quarter.
- Ordinary-course litigation was disclosed; management did not expect resolution to result in a material payment. No impairment of goodwill, intangible assets or other long-lived assets was identified at June 30. The company was evaluating the effect of the new revenue-recognition standard, effective for its fiscal year beginning April 1, 2017, and could not yet estimate the impact.
- Management reported effective disclosure controls. The CFO changed during the quarter, and certain control responsibilities were reassigned; the company said it would continue monitoring internal controls.
Important facts for investors to verify
- Confirm the intended reporting period: the supplied filing covers the quarter ended June 30, 2014, not 2013.
- Track whether patient-management growth continues and whether its lower-margin mix further pressures gross margin.
- Review subsequent renewal or replacement of the credit facility due in September 2014.
- Assess operating cash-flow conversion, accrued-liability movements, and ongoing repurchases against liquidity and investment commitments.
- Monitor IT spending, software execution, and the company’s exposure to customer, regulatory, labor and claims-volume risks.